Skip to content
DataLookout
Menu

NCT07772531

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 13 words
    • Trial sites reduced: 27 → 24 locations
  2. Minor Study sites: 26 to 27v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score
Timeframe: Up to Day 57

Secondary (4)

Number of Participants with Treatment Emergent Adverse Events (AEs)
Number of Participants with Serious Adverse Events (SAEs)
Number of Participants with AEs Leading to Treatment Discontinuation
Number of Participants with AEs Leading to Death

Arms and interventions

BMS-986511: Dose AExperimental
BMS-986511: Dose BExperimental
PlaceboExperimental

Drugs: BMS-986511, Placebo

Sites

24 sites in 2 countries

United States 18, Czechia 6